Deputy Director Named for FDA’s Division of Oncology Drug Products

Publication
Article
OncologyONCOLOGY Vol 16 No 4
Volume 16
Issue 4

Grant Williams, MD, recently assumed the position of deputy director of the Division of Oncology Drug Products, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA). Dr. Williams joined the FDA in 1989 as a medical officer and was named oncology medical team leader in 1996.

Grant Williams, MD, recently assumed the position ofdeputy director of the Division of Oncology Drug Products, Center for DrugEvaluation and Research (CDER), US Food and Drug Administration (FDA). Dr.Williams joined the FDA in 1989 as a medical officer and was named oncologymedical team leader in 1996. Prior to joining the FDA, Dr. Williams completed aninternship and residency in internal medicine and a fellowship inhematology/oncology at the University of Alabama at Birmingham. He earned hismedical degree from the University of Alabama in 1982.

Exemplary Leadership

During his tenure at the FDA, Dr. Williams has served as the primary reviewerfor more than 15 new drug applications (NDAs)/efficacy supplements and asmedical team leader for more than 20 NDAs, including the imatinib mesylate (Gleevec)NDA that was completed in 2½ months. He organized a 17-course lecture seriesfor new oncology reviewers and has chaired the CDER’s Oncology CoordinatingCommittee since its inception in 2001.

Dr. Williams’ numerous other FDA-related activities have included writingthe Center for Biologics, Evaluation, and Research (CBER)-CDER OncologyGuidances, organizing oncology advisory committee meetings, and speaking to bothprofessional and patient advocacy groups.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content